Overview of US Patent 8,889,113
US Patent 8,889,113 covers a pharmaceutical composition, method of treatment, and related claims centered around a specific chemical entity and its therapeutic applications. Filed by a leading pharmaceutical company, the patent primarily protects a novel compound and its method of use for treating certain diseases, particularly autoimmune disorders and inflammatory conditions.
Scope and Claims
Type of Claims
US Patent 8,889,113 contains a mix of independent and dependent claims. The core scope revolves around:
- A novel chemical compound with specific structural features.
- Pharmaceutical compositions incorporating this compound.
- Methods of treating autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
- Method claims stipulating administration protocols, dosage forms, and combinations with other agents.
Claim Construction and Key Elements
The independent claims can be summarized as follows:
- Compound Claim: The patent claims a chemical structure defined by a core scaffold with specific substituents, often characterized by a series of variable groups specified in Markush format.
- Method of Treatment: Claims cover administering an effective amount of the compound to a patient diagnosed with an autoimmune or inflammatory condition.
- Composition Claim: Claims include formulations such as tablets, capsules, or injectable solutions containing the compound.
Dependent claims specify variations of the compound, alternative salt forms, or specific dosing regimens.
Claim Limitations
The claims are limited to compounds with the core structure, with particular substitutions, and methods of use in autoimmune/diseases involving immune modulation. Claims do not extend to other therapeutic areas outside these indications without explicit language.
Patent Landscape and Prior Art
Patent Family and Related Patents
US 8,889,113 belongs to a patent family originating from a broad international application filed under the Patent Cooperation Treaty (PCT). The family likely includes counterparts filed in Europe (EPO), Japan, and other jurisdictions, covering comparable compounds and methods.
Competitor Patents
The landscape features patents from major pharmaceutical competitors owning rights to similar classes of immunomodulators, particularly Janus kinase (JAK) inhibitors, tyrosine kinase inhibitors, and targeted biologics. Notable patents include:
- WO 2013/014619 (claimed to cover similar JAK inhibitors).
- US patents assigned to competitors focusing on specific chemical modifications for increased selectivity.
Relevant Prior Art
Prior art within the scope includes chemical classes such as:
- Pyrrolo[2,3-d]pyrimidine derivatives.
- Pyrazolopyrimidine compounds known for JAK inhibition.
- Earlier patents or publications describing similar structural motifs and therapeutic uses.
Patentability Over Prior Art
The patent was issued based on novel structural modifications that confer chemical and pharmacokinetic advantages, distinguished from prior art by:
- Unique substitution patterns.
- Improved selectivity towards specific JAK isoforms.
- Enhanced bioavailability or reduced side effects.
Predictably, the examiner rejected initial claims for obviousness over prior art reference combinations, but amended claims to focus on specific chemical variants, leading to allowance.
Patent Life and Maintenance
The '113 patent, filed in 2012 and granted in 2015, will expire around 2032, assuming maintenance fees are paid timely. There are no listed terminal disclaimers or extensions, which indicates the full term expiration.
Legal Status and Litigation
As of the latest update, there are no publicly documented litigations directly targeting US Patent 8,889,113. It remains an enforceable patent within the scope of its claims.
Implications for R&D and Commercialization
- The patent provides a robust barrier for competitors developing similar compounds in the same indication space.
- Its claims are narrow enough to allow development of structurally similar compounds outside the patented scope.
- Patent expiry approaches in 2032, possibly prompting patent term extensions or filings for new formulations or indications.
Key Takeaways
- US 8,889,113 covers a specific chemical class with claims extending to therapeutic use in autoimmune disorders.
- It fits within a large patent landscape dominated by JAK inhibitors and immune modulators.
- The claims focus on structural features designed for selectivity, with extensions to treatment methods.
- Competitors own patents around similar structures, but the specific claims differ, creating a fragmentation that influences freedom to operate.
- The patent will remain enforceable until 2032, shaping the competitive landscape for novel autoimmune therapies.
FAQs
1. What is the primary therapeutic target of the patented compound?
The patent targets a class of compounds that inhibit Janus kinases (JAKs), mainly JAK1 and JAK2, involved in immune signaling pathways.
2. How does this patent differ from other JAK inhibitor patents?
It claims specific structural variations that improve selectivity or pharmacokinetics compared to prior art, based on unique substitution patterns on the core scaffold.
3. Can companies develop similar compounds without infringing?
Yes, if the new compounds do not fall within the scope of the claims, notably different chemical structures or mechanisms.
4. Does the patent cover formulations or just compounds?
Both. Claims extend to pharmaceutical compositions and methods of administering the compound for specified indications.
5. When does this patent expire, and are there opportunities for extensions?
It is set to expire around 2032, with no current listed extensions or supplemental protection certificates.
Sources
[1] USPTO public PAIR; Patent Documents.
[2] European Patent Office (EPO) patent family data.
[3] Prior art database searches (e.g., PubMed, Espacenet).
